Satellos changes Duchenne trial endpoint to MRI fat fraction for forazapadin; Amgen's Repatha beats Zetia; MetaVia's DA-1726 ...
In an early test of two bispecific T cell engagers combined in a solid tumor, Immunocore said an estimated 70% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results